ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,370Medicare Part D Prescriptions Filled, Including Refills

Rank: 165 out of 1006

$502K Total Retail Price of All Prescriptions

Rank: 223 out of 1006

428 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 428 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

8% of this provider’s 428 patients filled at least one prescription for a schedule three drug, compared to an average of 4%.

Risky Drugs to Seniors

1% of this provider’s 7,275 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
SIMVASTATIN 346 312 1 1
LISINOPRIL 323 286 2 3
FUROSEMIDE 298 257 3 6
HYDROCHLOROTHIAZIDE 268 242 4 11
LEVOTHYROXINE SODIUM 234 225 5 2
METFORMIN HCL 209 187 6 10
ATENOLOL 177 177 7 13
AMLODIPINE BESYLATE 174 146 8 4
ATORVASTATIN CALCIUM 173 135 9 5
METOPROLOL TARTRATE 166 158 10 7
WARFARIN SODIUM 165 165 11 8
ZOLPIDEM TARTRATE 129 117 12 14
OMEPRAZOLE 128 119 13 9
TAMSULOSIN HCL 113 113 14 23
TRAMADOL HCL 107 62 15 35
CARVEDILOL 105 94 16 36
PROAIR HFA 104 70 17 64
LOVASTATIN 97 97 18 44
ALLOPURINOL 95 72 19 31
LISINOPRIL-HYDROCHLOROTHIAZIDE 95 80 19 38
METOPROLOL SUCCINATE 95 85 19 12
TRIAMTERENE-HCTZ 89 76 22 58
GLIPIZIDE 88 82 23 69
LOSARTAN POTASSIUM 86 73 24 22
HYDROCODONE-ACETAMINOPHEN 85 79 S3 25 25
SYNTHROID 84 76 26 42
SERTRALINE HCL 81 77 27 19
LANTUS 81 57 27 43
PRAVASTATIN SODIUM 80 72 29 15
NEXIUM 75 35 30 28
ADVAIR DISKUS 72 48 31 37
CITALOPRAM HBR 67 61 32 24
DIGOXIN 65 50 33 52
LANTUS SOLOSTAR 62 38 34 93
LEVETIRACETAM 60 60 35 72
LABETALOL HCL 59 59 36 164
DIOVAN 59 59 36 16
DILTIAZEM 24HR ER 56 53 38 126
PAROXETINE HCL 56 51 38 62
INSULIN SYRINGE 56 52 38 122
SPIRIVA 55 34 41 48
POTASSIUM CHLORIDE 55 55 41 30
PANTOPRAZOLE SODIUM 55 43 41 32
TRAZODONE HCL 53 25 44 21
PREDNISONE 52 40 45 33
GABAPENTIN 52 49 45 20
NIFEDIPINE ER 50 50 47 166
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 10, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.